Expansion of the biologics production facility in denmark

FUJIFILM Diosynth Biotech­nolo­gies, a con­tract devel­op­ment and man­u­fac­tur­ing orga­ni­za­tion (CDMO) for bio­log­ics, viral vac­cines and viral vec­tors, held a vir­tu­al ground-break­ing cer­e­mo­ny today to cel­e­brate the start of its large scale cell cul­ture expan­sion project. The major cap­i­tal invest­ment of 100 bil­lion yen (928 mil­lion USD) was pre­vi­ous­ly announced in June 2020.
The expan­sion will dou­ble the exist­ing bulk drug sub­stance pro­duc­tion capac­i­ty with the addi­tion of 6 x 20,000L biore­ac­tors, bring­ing the total to 12 x 20,000-liter biore­ac­tors. The new con­struc­tion will also include a ful­ly auto­mat­ed, cut­ting-edge fill/finish capa­bil­i­ty to sup­port large-scale pro­duc­tion of up to approx­i­mate­ly 35 mil­lion units per annum. To sup­port the expand­ed oper­a­tions, the com­pa­ny will add 300 posi­tions in Den­mark by the end of 2023.
The expan­sion invest­ment also includes a new pack­ag­ing line designed to assem­ble mul­ti­ple types of auto-injec­tors and auto­mat­ic labelling; these capa­bil­i­ties will be oper­a­tional in spring 2022. The fill/finish pro­duc­tion line is expect­ed to be oper­a­tional by sum­mer 2023. As the final step in the con­struc­tion, the large scale cell bulk drug sub­stance expan­sion is expect­ed to be oper­a­tional by the end of 2023.

“I am very proud that Fuji­film has cho­sen to make such a sig­nif­i­cant invest­ment in Hillerød. We are com­mit­ted to fos­ter a good busi­ness envi­ron­ment, and have always had a fruit­ful and good col­lab­o­ra­tion with Fuji­film, and I look for­ward to wel­com­ing even more Fuji­film employ­ees to our municipality.”
— Kirsten Jensen, May­or of Hillerød

Today’s event includ­ed mes­sages from His Excel­len­cy Miya­gawa Man­abu, Ambas­sador of Japan in Den­mark; Mr. Takatoshi Ishikawa, Senior Exec­u­tive Vice Pres­i­dent, Gen­er­al Man­ag­er, Ms. Kirsten Jensen, May­or of Hillerød and Mr. Toshi­hisa Iida, Pres­i­dent and Man­ag­ing Direc­tor in Europe.
“It was a delight to cel­e­brate the com­mence­ment of this very impor­tant expan­sion,” said Takatoshi Ishikawa, Senior Exec­u­tive Vice Pres­i­dent, Gen­er­al Man­ag­er of Bio CDMO Divi­sion, FUJIFILM Cor­po­ra­tion. “The com­pa­ny has high­light­ed the CDMO busi­ness as a pri­or­i­ty growth area, and is active­ly invest­ing in tech­nol­o­gy to expand its man­u­fac­tur­ing capac­i­ty to meet the grow­ing demands of cus­tomers. Addi­tion­al­ly, as the largest invest­ment in Europe for Bio CDMO busi­ness, this new facil­i­ty rep­re­sents our com­mit­ment to grow­ing our Bio CDMO offer­ing in the region to bet­ter serve our customers.”

“The expan­sion will be trans­for­ma­tive, sig­nif­i­cant­ly expand­ing our abil­i­ty to sup­port cur­rent and future part­ners, infus­ing sus­tain­abil­i­ty efforts into future oper­a­tions, and fur­ther strength­en­ing our lead­er­ship in bio­log­ic drug sub­stance man­u­fac­tur­ing. We are excit­ed to see the site grow and to wel­come 300 new employees.”
— Lars Petersen, Chief Oper­at­ing Offi­cer and Senior Vice President